JUBLPHARMA

Q4 2025 Result Analysis

Q4FY25 & FY25 Results: Q4FY25: Revenue: ₹1,929 crore (+10% YoY) EBITDA: ₹357 crore (+23%), margin at 18.4% (+210 bps) Reported PAT: ₹151 crore (vs loss of ₹62 crore last year) FY25: Revenue: ₹7,628 crore (+8%) EBITDA: ₹1,434 crore (+24%), margin at 18.7% (+220 bps) Reported PAT: ₹572 crore (+1,050%) Net debt/EBITDA improved to 1.1x (from 2.5x) after $125M debt repayment Key Business Highlights: Strong growth across Radiopharma, Allergy Immunotherapy, CDMO, and CRDMO Launched prostate cancer diagnostic Pylarify® Profitability achieved in generics; new biologics capabilities added US CDMO business seeing strong demand due to tariff risk mitigation by pharma companies Vision 2030 Progress: On track to double revenue, improve EBITDA margin to 23–25%, eliminate net debt, and boost return on capital Overall, Jubilant Pharmova delivered strong financial and operational performance in FY25, with significant margin improvement, debt reduction, and strategic growth positioning, especially in the US CDMO market.